// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Real-World Effectiveness of Infliximab in the Treatment of Psoriatic Arthritis over 12 Months: The Canadian Experience

Majed Khraishi - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Infliximab

Safety Update on Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure

Ronald Van Vollenhoven - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Rheumatoid arthritis

Certolizumab pegol

Non-Radiographic Axial Spondyloarthritis Has Greater Work Instability than Other Spondyloarthritis Subtypes

Robert Inman - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

N/A

Prevalence of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity in Psoriatic Arthritis Patients: Impact of Treatment with TNF Inhibitors in a Real-World Canadian Population

Denis Choquette - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Infliximab

Rheumatology Patient Triage: Family Physician Preferences and Feedback

Steven Katz - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Autoantibodies in Systemic Sclerosis and Risk of Organ Involvement: Results from a Large SSc cohort {Canadian Scleroderma Research Group (CSRG)

Carly Hewson - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Electrocardiogram Abnormalities in Systemic Sclerosis - Systematic Review of the Literature

Murray Baron - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Tensegrity: The Importance of Mechanical Forces in Scleroderma Fibrosis

Katherine Thompson - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Incidence and Characteristics of Atypical Femoral Fractures

Sonia Jean - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

TNF-Inhibitors Slow Radiographic Progression of Ankylosing Spondylitis

Robert Inman - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

Identification of Four Parameters that Drive the Discordance between the Patient and Physician Global Assessment in Rheumatoid Arthritis

Denis Choquette - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Infliximab

Validation of SNAPSHOT As a Rheumatoid Arthritis Clinical Assessment Tool

Melissa Deamude - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Vitamin D in Obesity (VIDeO): Assessing Vitamin D Deficiency in the Bariatric Population, a Quality Assurance Initiative

Maria Tiboni - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Vitamin D deficiency

Ergocalciferol

Microparticle-Associated Immune Complexes Derived from Platelets are Elevated in the Plasma of Patients with Systemic Lupus Erythematosus and Discriminate between Levels of Disease Activity

Eric Boilard - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Prednisone

Are there Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Rheumatoid Arthritis?

Denis Choquette - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Infliximab

Self Management Strategies of Rheumatoid Arthritis Patients Experiencing a Disease Flare

Clifton Bingham - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria Predicts Radiogical, but Not Clinical Outcomes at 18 Months into Disease in a Canadian Early Arthritis Cohort

Artur De Brum-Fernandes - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

The ACR/EULAR Classification Criteria for Systemic Sclerosis (SSc).

Dinesh Khanna - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Reliability of the Early Erosions in Rheumatoid Arthritis Software when Quantifying Bone Loss

Melissa Koh - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

The Impact of Reaching Low Disease Activity in the First Year on Future Disability and Damage in Patients with Early Rheumatoid Arthritis

George Tomlinson - Canadian Rheumatology Association (CRA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Copyright © 2026. QuantiNova All rights reserved